NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a small share disposition related to taxes, not an open-market trade. On this Form 4, 906 shares of common stock were withheld at $0.777 per share to satisfy a tax obligation. Following this tax-withholding disposition, Mertens directly holds 152,141 shares of common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp director and CEO David A. Rosa reported a tax-related share disposition. On the reported date, 2,458 shares of Common Stock were delivered at $0.777 per share as a tax-withholding disposition to cover exercise price or tax liabilities. After this non-market transaction, he directly owned 1,080,132 shares of Common Stock.
NEUROONE MEDICAL TECHNOLOGIES Corp executive Mark Christianson, Business Development Director, reported small open-market sales of company common stock. He sold 817 shares on March 12, 2026 and 100 shares on March 13, 2026, both at $0.80 per share. After these transactions, he directly holds 214,283 shares of NeuroOne common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp officer Mark Christianson reported open-market sales of a total of 13,720 shares of common stock at weighted average prices around $0.80 per share on March 10–11, 2026. After these transactions, he directly holds 215,200 shares of common stock.
NeuroOne Medical Technologies Corporation is asking stockholders to vote at its April 3, 2026 annual meeting on key governance and capital-structure items. Routine matters include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor, and amending the 2025 Equity Incentive Plan.
The most significant proposal would authorize the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-15 any time within one year, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The split would reduce outstanding shares but leave authorized shares unchanged, increasing the number of authorized, unissued shares.
The equity plan amendment would add 1,500,000 shares to the 2025 Equity Incentive Plan and introduce a five-year “evergreen” feature allowing annual increases of up to 5% of fully diluted shares from 2027 through 2031. Stockholders are also asked to approve the ability to adjourn the meeting to solicit more proxies if needed for the reverse split proposal.
NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.
NEUROONE MEDICAL TECHNOLOGIES Corp executive David J. Wambeke, the company’s Chief Business Officer, filed an initial Form 3 reporting his beneficial ownership in the company. The filing does not list any insider buy or sell transactions; it simply establishes his status as a reporting officer.
NeuroOne Medical Technologies Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held April 3, 2026 at its Eden Prairie, MN offices. Stockholders will vote to elect two Class III directors, ratify Baker Tilly as auditor, approve a Board-authorized reverse stock split (a 1-for-2 to 1-for-15 range), approve an amendment to the 2025 Equity Incentive Plan, and authorize adjournments to solicit additional proxies.
The record date for voting is February 20, 2026; 50,693,017 shares of Common Stock were outstanding as of that date. The Board may select the final reverse-split ratio and timing if stockholders approve the range.